Fresenius Medcl Drug Patent Portfolio
Fresenius Medcl's Family Patents
Recently granted tentative Approvals to Fresenius Medcl
These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Fresenius Medcl's portfolio.
Innovator tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Cabazitaxel | Cabazitaxel |
SUPPL-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 22 Nov, 2019 |
Generic tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Bendamustine Hydrochloride | Bendamustine Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 13 Nov, 2018 |
Explore deeper patents analysis
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List